Commentary: Data monitoring confidentiality and FDA transparency

被引：3

|

作者：

London, Alex John ^{[1
]}

机构：

[1] Carnegie Mellon Univ, Dept Philosophy, Ctr Eth & Policy, Pittsburgh, PA 15213 USA

来源：

CLINICAL TRIALS | 2015年 / 12卷 / 01期

关键词：

CLINICAL-TRIALS; INTERIM DATA;

D O I：

10.1177/1740774514561047

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

收藏

页码：12 / 14

页数：3

相关论文

共 50 条

[1] FDA considers data confidentiality for diabetes drugs
Traynor, Kate
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (19) : 1607 - 1608
[2] Commentary: Preserving confidentiality of interim data
Chuang-Stein, Christy
Jiang, Qi
Marchenko, Olga
CLINICAL TRIALS, 2015, 12 (01) : 18 - 20
[3] FDA Seeks Transparency in Data and Decisions
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2010, 23 (07) : 18 - 19
[4] Commentary: Preserving confidentiality of interim data Response
Fleming, Thomas R.
CLINICAL TRIALS, 2015, 12 (01) : 21 - 23
[5] FDA and the Importance of Confidentiality
Rosen, David L.
BIOPHARM INTERNATIONAL, 2012, 25 (10) : 74 - +
[6] Beyond data: Transparency and trust Commentary
Silvestry, Scott C.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 164 (06): : 1943 - 1944
[7] Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters
Shah, Seema K.
Eckstein, Lisa
Ibrahim, Akram
CLINICAL TRIALS, 2023, 20 (04) : 452 - 454
[8] Reproducibility and transparency versus privacy and confidentiality: Reflections from a data editor
Vilhuber, Lars
JOURNAL OF ECONOMETRICS, 2023, 235 (02) : 2285 - 2294
[9] Commentary: Confidentiality of interim trial data-The emerging crisis
Nissen, Steven E.
CLINICAL TRIALS, 2015, 12 (01) : 15 - 17
[10] FDA PRE-MARKET APPROVAL OF NEW MEDICAL DEVICES - CONFIDENTIALITY OF DATA
JACOBS, JA
FOOD AND DRUG LAW JOURNAL, 1980, 35 (10): : 576 - 587

← 1 2 3 4 5 →